Yahoo Web Search

  1. Ads
    related to MERCK & CO., INC
  1. Does the August share price for Merck & Co., Inc. (NYSE:MRK) reflect what it's really worth? Today, we will estimate the stock's intrinsic value by taking the foreast future ...

  2. EVP&Pres, Merck Animal Heallth of Merck & Co Inc (30-Year Financial, Insider Trades) Richard R. Deluca (insider trades) sold 38,126 shares of MRK on 08/09/2019 at ...

  3. Kahn Brothers' Top 6 Buys in the 2nd Quarter

    GuruFocus.com via Yahoo FinanceAug 06 21:26 PM

    Kahn Brothers (Trades, Portfolio), founded by legendary investor Irving Kahn, disclosed this week its top six buys for the second quarter were Merck & Co. Inc. (NYSE:MRK ...

  4. PD-L1 inhibitors available on the market are Merck’s MRK Keytruda, AstraZeneca’s AZN Imfinzi, Bristol Myers’ BMY Opdivo, Roche’s Tecentriq and Pfizer’s PFE Bavencio. ...

  5. Biotech stocks hitting 52-week lows on Aug. 5) Acer Therapeutics Inc (NASDAQ: ACER) Aclaris Therapeutics Inc (NASDAQ: ACRS) Actinium Pharmaceuticals Inc (NYSE: ATNM) Adaptimmune ...

  6. Lexicon Pharmaceuticals, Inc. NASDAQ: LXRX) was a huge casualty as the micro-cap stock fell steeply on severing of a licensing pact with Sanofi SA (NASDAQ: SNY).

  7. Esperion (ESPR) Q2 Loss Wider Than Expected, Revenues Beat

    Zacks via Yahoo FinanceAug 09 12:06 PM

    Esperion Therapeutics, Inc. ESPR incurred a loss of $2.01 per share in the second quarter of 2019, wider than the Zacks Consensus Estimate of $1.86. The company had incurred loss of $1.71 per share in the year-ago period.

  8. Intrexon (XON) Reports Narrower-Than-Expected Loss in Q2

    Zacks via Yahoo FinanceAug 09 14:59 PM

    Intrexon Corporation XON incurred a loss of 21 cents per share (excluding a non-cash charge of $8 million) in second-quarter 2019, narrower than a loss of 24 cents in the year-ago period and ...

  9. Moleculin Completes Enrollment in Early-Stage Cancer Study

    Zacks via Yahoo FinanceAug 15 11:55 AM

    Moleculin Biotech, Inc. MBRX announced that it has completed enrollment in the proof-of-concept clinical study evaluating its p-STAT3 inhibitor candidate, WP1220...skin cancer. The company ...

  10. Benzinga has examined the prospects for many investor favorite stocks over the past week. Bullish calls included an underappreciated automaker and a leading pharmaceutical. Bearish calls included FAANG stocks and an aerospace giant.

  1. Ads
    related to MERCK & CO., INC